REG - hVIVO PLC - >£5 million CRS contracts signed

hVIVOAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251120:nRST2647Ia&default-theme=true

RNS Number : 2647I  hVIVO PLC  20 November 2025

hVIVO plc

("hVIVO", the "Company" or the "Group")

 

>£5 million CRS contracts signed

 

hVIVO plc (AIM: HVO), a full-service early phase Contract Research
Organisation (CRO) and the world leader in human challenge clinical trials,
announces its German subsidiary CRS, has signed contracts worth over £5
million since September.

 

The early-phase clinical trial service contracts have been signed with five
clients, including two returning mid-sized German pharma customers reaffirming
CRS' strong reputation and long-standing relationships in Germany. These
pharma partnerships, given their volume and consistency, strengthens the
Group's sales pipeline and orderbook for 2026 and beyond. These trials are due
to commence this year and H1 2026 with the majority of revenue recognised in
2026.

 

The trials will take place at the Mannheim and Kiel sites studying drug
candidates targeting multiple therapeutic areas including cardiometabolic,
dermatology, infectious disease, renal impairment, and cancer. CRS has strong
expertise across this range of therapeutic areas, expanding the Group's
addressable market. Venn Life Sciences will be supporting these contracts with
its Biometry service, demonstrating the cross-selling benefits being realised
from the integration of CRS into the Group.

 

CRS have conducted over 1,800 clinical trials and provides advice to its
clients across every aspect of their study, from feasibility and study design
to trial management, recruitment, execution, and close-out. These studies span
Phase I and Phase II in healthy volunteers and patients, supported by CRS'
participant recruitment platform, recently enhanced by hVIVO's Volunteer
Management System improving efficiency in recruitment for CRS trials.

 

Dr Yamin 'Mo' Khan, Chief Executive Officer of hVIVO, said: "Securing over
£5 million in new contracts, including two mid-sized pharma clients,
underscores our strong reputation and the strategic importance of CRS within
the Group. These wins demonstrate the success of our integration strategy and
the value we deliver through combined expertise across the hVIVO Group. CRS
has seen an increased conversion rate of proposals to contracts year-to-date
versus 2024 and with a robust sales pipeline and continued efficiency
improvements, CRS remains on track to become earnings accretive in 2026."

 

Professor Thomas Forst, Chief Medical Officer of hVIVO, said: "At CRS, we are
committed to delivering high-quality clinical trial services that accelerate
the development of safe and effective medicines for patients worldwide. These
new studies span multiple therapeutic areas and showcase the depth of our
expertise and the trust our clients place in us. By combining scientific
excellence with operational efficiency, we continue to strengthen our position
as a leading partner for early-phase clinical research."

 

For further information please contact:

 

 hVIVO plc                                       +44 (0)20 7756 1300
 Yamin 'Mo' Khan, Chief Executive Officer

 Stephen Pinkerton, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser                                                  +44 (0)20 7220 0500

and Joint Broker)
 Geoff Nash, Callum Davidson,

Trisyia Jamaludin, Harriet Ward

 Nigel Birks - Life Science Specialist Sales

 Louise Talbot - Sales

 Peel Hunt LLP (Joint Broker)                                               +44 (0)20 7418 8900
 James Steel, Dr Christopher Golden

 Davy (Joint Broker)                                                        +353 (0) 1 679 6363
 Anthony Farrell, Niall Gilchrist

 Walbrook PR (Financial PR & IR)                 +44 (0)20 7933 8780 or hvivo@walbrookpr.com (mailto:hvivo@walbrookpr.com)

 Paul McManus / Alice Woodings /                 +44 (0)7980 541 893 / +44 (0)7407 804 654/

+44 (0)7584 391 303
 Lianne Applegarth

 

 

Notes to Editors

hVIVO plc (https://hvivo.com/)  (Ticker: HVO) is full-service early phase
Contract Research Organisation (CRO) and the global leader in human challenge
trials. The company delivers end-to-end clinical development services to a
diverse and expanding client base, including seven of the world's ten largest
biopharma companies.

 

hVIVO specialises in conducting human challenge trials across multiple
infectious and respiratory indications, leveraging its state-of-the-art
quarantine facility in London-the largest of its kind worldwide. The Company
also offers comprehensive virology and immunology laboratory services under
the hLAB (https://hlabservices.com/)  brand.

 

Through its German subsidiary, CRS (https://crs-earlyphase.com/) , hVIVO
operates a 120-bed capacity across Mannheim and Kiel, providing early-phase
clinical trial services, including first-in-human and proof-of-concept
studies. Its second subsidiary, Venn Life Sciences
(https://www.vennlifesciences.com/) , offers Early Drug Development
Consulting and Biometry services to the biopharma sector.

 

The Group provides fully integrated drug development solutions from
preclinical stages through Phase II trials, alongside patient recruitment
via FluCamp (https://flucamp.com/) . Additionally, its five clinical sites
support outpatient Phase II and III trials, ensuring a seamless and
efficient pathway from discovery to late-stage development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTFFUESUEISEIF



            Copyright 2019 Regulatory News Service, all rights reserved